...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Pediatric intestinal retransplantation: techniques, management, and outcomes.
【24h】

Pediatric intestinal retransplantation: techniques, management, and outcomes.

机译:小儿肠移植:技术,管理和结果。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Intestinal retransplantation (Re-ITx) has historically been associated with high morbidity and mortality. METHODS: The outcomes of all children receiving Re-ITx between 1990 and 2007 at our center were reviewed. RESULTS: One hundred seventy-two children received primary intestinal grafts. Fourteen children (8.1%) were retransplanted with 15 grafts. Causes of graft failure were acute cellular rejection (ACR, n=4), liver failure (n=2), chronic rejection (n=3), posttransplant lymphoproliferative disorder (n=1), graft dysmotility or dysfunction (n=3), ACR with severe infection (n=1), and arterial graft aneurysm (n=1). Initial transplants were isolated bowel in nine, liver-bowel in five, and one multivisceral. The mean time of initial graft survival was 34.2 months. Re-ITx was with isolated bowel in two, liver-bowel in four, and multivisceral in nine (four with kidney). Initial immunosuppression was Tac-Pred based in nine and rabbit antithymocyte globulin-Tac based in six cases. Re-ITx was carried out under Tac-Pred in six, rabbit antithymocyte globulin-Tac in eight, and alemtuzumab monoclonal anti-CD52 antibody in one. Ten (71.4%) patients are alive with functioning grafts at a mean current follow-up time of 55.9 months. Four patients died from posttransplant lymphoproliferative disorder, severe ACR, fungal sepsis, and bleeding from pseudoaneurysm, respectively, at a mean time of 5.7 months post-Re-ITx. All surviving patients weaned-off total parenteral nutrition at a median time of 32 days and 90% are off intravenous fluids. CONCLUSIONS: Improved long-term survival and outcome in pediatric Re-ITx may be attributed to improvements in initial immunosuppression protocols, technical modifications, proper timing, and improved infectious disease monitoring. Careful patient selection and posttransplant management are essential for successful long-term outcome.
机译:背景:肠道再移植(Re-ITx)历来与高发病率和高死亡率有关。方法:我们对1990至2007年间所有接受Re-ITx治疗的儿童的结局进行了回顾。结果:172名儿童接受了原肠移植。 14个儿童(8.1%)被移植了15个移植物。移植失败的原因包括急性细胞排斥反应(ACR,n = 4),肝衰竭(n = 2),慢性排斥反应(n = 3),移植后淋巴增生性疾病(n = 1),移植物运动障碍或功能障碍(n = 3) ,严重感染的ACR(n = 1)和动脉移植瘤(n = 1)。最初的移植是在9个肠道中分离出肠,在5个中分离肝肠,和1个是多脏器。初始移植物存活的平均时间为34.2个月。 Re-ITx的肠胃分离为二分,肝肠为四分,多脏器为九分(肾脏四分)。最初的免疫抑制是基于Tac-Pred的,有9例,基于兔抗胸腺细胞球蛋白-Tac的,有6例。 Re-ITx在Tac-Pred中以六种进行,兔抗胸腺细胞球蛋白-Tac在八种中进行,而alemtuzumab单克隆抗CD52抗体在一种中进行。十名(71.4%)患者在正常情况下的55.9个月的平均随访时间内存活,且功能正常。在Re-ITx后平均5.7个月,分别有4例患者死于移植后淋巴细胞增生性疾病,严重的ACR,真菌性败血症和假性动脉瘤出血。所有存活的患者在32天的中途断奶了全部肠胃外营养,其中90%的患者不使用静脉输液。结论:小儿Re-ITx的长期生存和转归改善可能归因于初始免疫抑制方案,技术改造,适当时机和传染病监测的改善。仔细的患者选择和移植后管理对于长期成功的成功至关重要。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号